Drugs / E-WE Thrombin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03453060 | May → Nov 2018 | thrombotic disease | Aronora, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E-WE Thrombin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03453060 ↗ |
| Known as | AB002 | “AB002 (E-WE thrombin) is an investigational protein C activator thrombin analog in phase 2 clinical development” PMID 31977000 ↗ Feb 2020 |
| Action | Activate | “AB002 (E-WE thrombin) is an investigational protein C activator thrombin analog” PMID 31977000 ↗ Feb 2020 |
| Modality | Protein / enzyme biologic | “AB002 (E-WE thrombin) is an investigational protein C activator thrombin analog” PMID 31977000 ↗ Feb 2020 |
| Route | Intravenous | “Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.” NCT03453060 ↗ |